Aug 22, 2024 8:30 am EDT Kane Biotech Announces Distribution Agreement with Razan Medical Trading for revyve™ Antimicrobial Wound Gel
Aug 13, 2024 8:30 am EDT Kane Biotech Receives Funding Support to Expand the revyve™ Antimicrobial Wound Gel Family
Jul 23, 2024 8:30 am EDT Kane Biotech Receives FDA Approval to Increase Dosage Allowance of its revyve™ Antimicrobial Wound Gel
Jul 11, 2024 8:30 am EDT Kane Biotech Signs Worldwide License Agreement with Omni Bioceutical Innovations Inc.
Jun 27, 2024 8:30 am EDT Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global
Jun 25, 2024 8:30 am EDT Kane Biotech Signs Worldwide License Agreement with Montreal-Based I-MED Pharma Inc.
May 16, 2024 8:00 am EDT Kane Biotech to Release First Quarter 2024 Financial Results on May 23, 2024
